 |
13 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- || HQK 1001 / Viracta Therap
Review, Journal: Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias. (Pubmed Central) - Jan 14, 2023
Data on adverse effects and optimal doses are limited. Five studies are awaiting classification, but none are ongoing.
- | HQK 1001 / Viracta Therap
Trial termination: Effects of HQK-1001 in Patients With Sickle Cell Disease (clinicaltrials.gov) - Nov 25, 2013
P2, N=77, Terminated, Sponsor: HemaQuest Pharmaceuticals Inc.
Five studies are awaiting classification, but none are ongoing. Active, not recruiting --> Terminated
- HQK 1001 / Viracta Therap
Trial completion: Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand (clinicaltrials.gov) - Mar 11, 2013
P2, N=10, Completed, Sponsor: Boston University
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- HQK 1001 / Viracta Therap
Trial completion: LB-04-THAL: Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (clinicaltrials.gov) - Mar 5, 2013
P2, N=10, Completed, Sponsor: Boston University
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- HQK 1001 / Viracta Therap
New P2 trial: LB-04-THAL: Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (clinicaltrials.gov) - Jul 15, 2012
P2, N=10, Completed, Sponsor: Boston University
- HQK 1001 / Viracta Therap
New P2 trial: Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand (clinicaltrials.gov) - May 30, 2012
P2, N=10, Completed, Sponsor: Boston University
- | HQK 1001 / Viracta Therap
New P2 trial: Effects of HQK-1001 in Patients With Sickle Cell Disease (clinicaltrials.gov) - May 16, 2012
P2, N=77, Terminated, Sponsor: HemaQuest Pharmaceuticals Inc.
- |||| HQK 1001 / Viracta Therap
Trial completion: A Study of HQK-1001 in Patients With Sickle Cell Disease (clinicaltrials.gov) - Apr 10, 2012
P2, N=52, Completed, Sponsor: HemaQuest Pharmaceuticals Inc.
Enrolling by invitation --> Completed Active, not recruiting --> Completed